Adhera Therapeutics (ATRX) News Today $0.0024 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC Filings All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Adhera Therapeutics Inc (ATRX)January 30, 2024 | investing.comATRX Adhera Therapeutics, Inc.August 24, 2023 | seekingalpha.comIntensity Therapeutics upsizes proposed IPO to $15M from $8MMay 22, 2023 | seekingalpha.comAdhera Therapeutics, Inc. (ATRX)February 27, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 25, 2023 | finance.yahoo.comCGTX Cognition Therapeutics, Inc.January 18, 2023 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringDecember 5, 2022 | seekingalpha.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsOctober 9, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistSeptember 19, 2022 | finance.yahoo.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistSeptember 19, 2022 | seekingalpha.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | seekingalpha.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsNovember 8, 2021 | finance.yahoo.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...October 20, 2021 | apnews.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsOctober 20, 2021 | finance.yahoo.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...October 16, 2021 | apnews.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s DiseaseOctober 15, 2021 | finance.yahoo.comAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasOctober 4, 2021 | finance.yahoo.com5 Penny Stocks with Upcoming Growth CatalystsSeptember 15, 2021 | insidermonkey.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...September 13, 2021 | apnews.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsSeptember 13, 2021 | finance.yahoo.comAdhera Therapeutics Appoints Dr. Andrew Reaume to Board of DirectorsSeptember 9, 2021 | finance.yahoo.comAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New ...August 24, 2021 | apnews.comAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug CandidateAugust 24, 2021 | finance.yahoo.comMelior Pharmaceuticals signs multimillion-dollar licensing deal for its experimental Parkinson's disease treatmentAugust 2, 2021 | bizjournals.comShares Spike On an Old Drug Being Used As a New Class of Drugs for Parkinson’s DiseaseJuly 29, 2021 | baystreet.caAdhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug CandidateJuly 29, 2021 | finance.yahoo.com Get Adhera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW ATRX Media Mentions By Week ATRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRX News Sentiment▼0.000.48▲Average Medical News Sentiment ATRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRX Articles This Week▼00▲ATRX Articles Average Week Get Adhera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TCON News NAVB News HENC News WCUI News ONBI News VAXX News AMPE News STAB News IMVIQ News EFTR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ATRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adhera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
